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（PD-L1）inhibitors have been reported to demon-
strate promising antitumor activity for non-small cell 
lung cancer, melanoma, renal cancer and such 6）. 
Although the anti-PD-1 antibody nivolumab was 
approved for unresectable malignant melanoma in 
Japan before anywhere else in the world, there are no 
reports of the anti-PD-1 antibody treatment for 
PMME that resulted in complete response（CR）. Here, 
we firstly report the efficacy of the anti-PD-1 anti-
body for malignant melanoma of the esophagus.
CASE REPORT
An 80-year-old woman, who had received treat-
ment for polymyalgia rheumatica, hypertension, and 
hyperlipidemia, presented to another clinic complain-
ing of progressive dysphagia in May 2015. She under-
went esophagogastroduodenoscopy, and a type 1 
tumor of the middle thoracic esophagus was discov-
INTRODUCTION
Squamous cell carcinoma accounts for approximate-
ly 90％ of esophageal cancers in Japan1～4）. Primary 
malignant melanoma of the esophagus（PMME）is 
extremely rare accounting for＜0.2％ of all of esopha-
geal cancers 5） with high malignancy and poor progno-
sis. However, an effective standard therapy for PMME 
remains to be established. In recent years, immune 
checkpoint inhibitors have emerged as promising 
therapeutic agents in several cancers. Programmed 
death 1（PD-1）protein/programmed death ligand-1
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SUMMARY
Primary malignant melanoma of the esophagus（PMME）is extraordinarily rare with a high degree of 
malignancy and poor prognosis, and a standard therapy remains to be established. The anti-PD-1 antibody 
nivolumab is a promising agent for various cancers. To our knowledge, this is the first case report of 
PMME where a complete response was achieved using nivolumab. We report an 80-year-old woman who 
was diagnosed with PMME with bone metastasis and lymph node metastases. Although dacarbazine com-
bined chemotherapy was performed and continued for six cycles, the primary tumor progressed and liver 
metastases appeared. The patient then received nivolumab monotherapy. After three cycles, nivolumab 
monotherapy for PMME resulted in a complete response as shown by positron emission tomography, com-
puted tomography, and esophagogastroduodenoscopy. In our case, nivolumab exerted a curative effect on 
PMME, thus suggesting that nivolumab can be effective in the treatment of this rare disease.
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ered（Fig. 1A, 1B）. The patient was then referred to 
our institution. Routine laboratory investigation 
results, including tumor maker levels, were normal in 
June 2015. Malignant melanoma was diagnosed by the 
initial biopsy because the tumor cells were positive 
for human melanoma black（HMB）-45 and Melan A 
but negative for anti-cytokeratins（AE1/AE3）, p40, 
and p63 by immunohistochemical analysis（Fig. 
1C-F）. There was no indication of invasion to the sur-
rounding organs. In addition, mediastinal and abdomi-
nal lymph node metastasis, and bone metastasis of the 
right femur were detected by computed tomography
（CT）and positron emission tomography（PET）（Fig. 
2A-C, 3A-D）. Finally, based on these results, we 
diagnosed the patient with unresectable PMME 
T3N1M1（bone）Stage IV, according to UICC/TMN 
Classification of Malignant Tumours, 7th edition, and 
planned the chemotherapy.
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Figure 1
The first esophagoscopy before the first treatment. Type 1 tumor is located in the middle thoracic esopha-
gus（A）. The tumor has a Lugol-voiding lesion（B）. Pathohistological examination and immunohistochemis-
try of the biopsy. Biopsy specimen showed proliferation of atypical cells that have hyperchromatic nuclei in 
Hematoxylin and eosin staining（C）. Tumor cells were positive for anti-cytokeratins（AE1/AE3）（D）, 
Melan-A（E）, and human melanoma black（HMB）-45（F）.
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Figure 2
CT before the first treatment. CT shows primary tumor（A）and lymph node metastases
（B, ５, white arrow）.
Figure 3
PET before the first treatment. Accumulation of fluorodeoxyglucose is demonstrated in middle 
thoracic esophagus（A）, including lymph node（B, C）and bone metastasis（D）.
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DAV therapy consisting of dacarbazine（140 mg/
m 2）, nimustine（80 mg/m 2）, and vincristine sulfate
（0.8 mg/m 2）was started in August 2015. We used 
the World Health Organization（WHO）Response Eval-
uation Criteria in Solid Tumor（RECIST）to estimate 
the effect of the chemotherapy. Although it indicated 
reduction in lymph node metastases and bone metas-
tasis after two cycles of DAV therapy, the primary 
tumor remained almost the same size, and also an 
accumulation of fluorodeoxyglucose（FDG）, and a liver 
metastasis appeared in S3 . Liver metastasis was 
detected only by PET. We continued to performed 
DAV therapy for four cycles because the primary 
tumor and metastases, except for the liver metastasis, 
were controlled and there were no adverse events. 
After four cycles, the lymph node and bone metasta-
ses disappeared but the primary tumor and liver 
metastasis progressed. In addition, a new liver metas-
tasis appeared in S6（Fig. 4A-C, Fig. 5A-D）. Progres-
sive disease remained after a total of six cycles；thus, 
we started the anti-PD-1 antibody（nivolumab）mono-
therapy in March 2016. Nivolumab（2 mg/kg, every 
three weeks）was administered for three cycles. After 
three cycles, CT showed that the primary tumor and 
multiple liver metastases（S3 , S6）had shrunken 
remarkably. PET also revealed the disappearance of 
FDG in each liver metastases and the primary tumor. 
Because CT and PET showed that the primary tumor 
and multiple liver metastases were entirely abolished, 
and esophagogastroduodenoscopy showed that the 
primary tumor was obliterated, the outcome of the 
PMME was graded as CR according to RECIST（Fig. 
6A-C, Fig. 7A-D）. There were no acute or late toxici-
ties associated with nivolumab. The patient has 
received nivolumab monotherapy in our hospital and 
CR has been maintained for five months.
DISCUSSION
Almost all malignant melanomas have been detect-
ed in the skin. PMME is extremely rare and difficult 
to cure because of its remarkably aggressive malig-
nancy with high ability to metastasize 7）. PMME com-
monly occurs in the sixth and seventh decades of life, 
with a male to female ratio of 2：1, and patients com-
Figure 4
CT after dacarbazine combined chemotherapy. The primary tumor was enlarged（A, white 
arrow）and liver metastases appeared in S3 and S6（B, C, white arrow）.
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Figure 5
PET after dacarbazine combined chemotherapy. Accumulations of fluorodeoxyglucose 
are increased in the middle thoracic esophagus（A）and appeared in S3 and S6（B, C）.
Figure 6
CT after PD-1 antibody monotherapy. The primary tumor（A, white arrow）and liver 
metastases（B, C, white arrow）shrank remarkably（A, white arrow）.
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plain of dysphagia, similar to other esophageal can-
cers. A standard treatment strategy remains to be 
established because of the limited number of cases 
and a limited evidence proving their efficacy；there-
fore, the current prognosis of PMME has yet to reach 
40％ as 5-year-survival 8,9）. Most current literature 
focuses on individual case reports, and the largest 
study of PMME was presented by Shugeng et al. in 
2016, which included 17 cases 10）. Surgical resection 
should be the first choice of treatment when patients 
have no distal metastases or bulky lymph node metas-
tases. Chemotherapy is an accepted common therapy 
for cases of inoperable malignant melanoma 10,11）, and 
dacarbazine, the most widely used chemotherapeutic 
agent for inoperable malignant melanoma, is common-
ly used as monotherapy or in combination. However, 
current trials have shown response rates of approxi-
mately 5-12％11～13） and these results had insufficient 
therapeutic efficacy. Needless to say, it is necessary to 
improve the current therapeutic methods.
In recent years, immune-checkpoint inhibitors have 
emerged as a promising therapy to improve the prog-
nosis of various cancers. PD-1/PD-L1 signaling is one 
of the key interactions between cancer cells and the 
immune system. Nivolumab is a human IgG4 anti 
PD-1 monoclonal antibody that regulates T cell acti-
vation to suppress tumor cell survival. Some reports 
have shown that the response rate of advanced malig-
nant melanoma treated with nivolumab therapy was 
approximately 28-31％14,15） and nivolumab improved 
overall survival compared with dacarbazine 16）.
Immune checkpoint inhibitors have the ability to 
induce strong tumor suppression, resulting in a pla-
teau in the tail of the survival curve 17）. In other 
words, long-lasting antitumor effects and improve-
ment of long-term prognosis can be expected in 
patients responding to immune checkpoint inhibitors. 
On the other hand, the response rate of immune 
checkpoint inhibitors is still inadequately low because 
of the lack of markers to select the population 
Figure 7
PET and esophagoscopy after anti PD-1 monotherapy. Accumulations of fluorodeoxyglu-
cose are completely abolished in the middle thoracic esophagus（A）, and S3 and S6（B, C）. 
Esophagoscopy also shows the absence of the primary tumor.
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responding to the immune checkpoint inhibitors. It is 
necessary to discover markers to select the respond-
ers in future studies. This case report is the first to 
have demonstrated that an unresectable PMME after 
dacarbazine combined chemotherapy gained CR by 
using nivolumab without acute and late toxicities. We 
believe this case will have a considerable impact on 
therapeutic strategies for PMME. It is hoped that new 
strategies or indications for PMME are developed.
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